Leukemia Therapy

TRAIL effective for purging leukemic cells from autologous stem cell grafts

Published in Cancer Weekly, August 19th, 2003

TRAIL shows promise for use as a purging agent to remove malignant cells from autologous stem cell grafts.

Researchers in South Korea conducted a study to "evaluate the potential of tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) to eradicate leukemia cell lines, while sparing normal hematopoietic stem cells."

"Human Jurkat and Molt-4 cell lines were used to optimize the purging process in umbilical cord blood (UCB) mononuclear cells," explained N.S. Lee and coauthors working at Soon Chun Hyang University Hospital in Seoul.

"The Jurkat cell line was TRAIL sensitive and TRAIL-resistant Molt-4 cell line became...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-08-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry